Last updated on March 2019

L. Casei DG in Patients With Irritable Bowel Syndrome.

Brief description of study

To assess the effect of L. casei DG (Lactobacillus paracasei CNCMI1572; Enterolactis plus) on abdominal symptoms and gut microbiota metabolism/composition in non constipated patients with IBS (Irritable Bowel Syndrome). Patients will be randomized to receive L. casei DG capsules, b.i.d. for 12 weeks the a 4 weeks Follow Up period will follow.

Clinical Study Identifier: NCT03449628

Find a site near you

Start Over